Overview

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
To learn if obinutuzumab in combination with CC-99282 can help to control previously untreated, high tumor burden FL
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Bristol-Myers Squibb
Treatments:
Obinutuzumab